Evotec
CVC
Active
Hamburg, Germany
27
50M
19
0.87
2
0.30
1
- Areas of investment
Summary
In 1993 was created Evotec, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Hamburg. The company was established in Europe in Germany.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this Corporate Investor is 6 percentage points less often commits exit comparing to other organizations.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Evotec, startups are often financed by Tech Coast Angels, Frontier IP Group plc, CARB-X. The meaningful sponsors for the fund in investment in the same round are Alexandria Venture, venBio Partners, Woodford Investment Management. In the next rounds fund is usually obtained by GT Healthcare Capital Partners, Celgene, CARB-X.
This organization was formed by Manfred Eigen.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Artificial Intelligence. The fund has no exact preference in some founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Carrick Therapeutics, Eternygen, Forge Therapeutics
Investor highlights
- Industry focus
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 27
- Lead investments
- 2
- Exits
- 1
- Rounds per year
- 0.87
- Follow on index
- 0.30
- Investments by industry
- Biotechnology (26)
- Health Care (16)
- Pharmaceutical (13)
- Therapeutics (11)
- Life Science (5) Show 10 more
- Investments by region
-
- France (4)
- Germany (6)
- United States (8)
- United Kingdom (6)
- Ireland (2) Show 1 more
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 32M
- Group Appearance index
- 0.85
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ARGOBIO | 02 Mar 2021 | Biotechnology | Early Stage Venture | 59M | Ile-de-France, Paris, France |
| BIORCHESTRA | 01 Mar 2017 | Health Care, Medical, Therapeutics, Biopharma | Seed | Gangwon-do, South Korea, South Korea | |
| OxVax | 21 Apr 2021 | Biotechnology, Therapeutics | Seed | Oxfordshire, Oxford, United Kingdom |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.